Supply Of Antimiganous Medications With The Following Active Ingredients, Erenumab, Galcanezumab, Fremanzumab, Eptinezumab, Rimegepant, Atogepant Destined For The Centers Of The Field Of Valencian Public Health.

Name: Supply Of Antimiganous Medications With The Following Active Ingredients, Erenumab, Galcanezumab, Fremanzumab, Eptinezumab, Rimegepant, Atogepant Destined For The Centers Of The Field Of Valencian Public Health.
Start: 2025-07-25
End: -0001-11-30
Location: Direccion General de Gestion Economica, Contratacion e Infraestructuras de la Conselleria de Sanidad

Direccion General de Gestion Economica, Contratacion e Infraestructuras de la Conselleria de Sanidad Spain has Released a tender for Supply Of Antimiganous Medications With The Following Active Ingredients, Erenumab, Galcanezumab, Fremanzumab, Eptinezumab, Rimegepant, Atogepant Destined For The Centers Of The Field Of Valencian Public Health. in Pharmaceuticals. The tender was released on Jul 25, 2025.

Country - Spain

Summary - Supply Of Antimiganous Medications With The Following Active Ingredients, Erenumab, Galcanezumab, Fremanzumab, Eptinezumab, Rimegepant, Atogepant Destined For The Centers Of The Field Of Valencian Public Health.

Deadline - login to view

GT reference number - 114145853

Product classification - Analgesics

Organization Details:

Address - Spain

Contact details - 565656565

Tender notice no. - 76454545

GT Ref Id - 114145853

Document Type - Tender Notices

Notice Details and Documents:

Description - Description: Supply of antimiganous medications with the following active ingredients, Erenumab, Galcanezumab, Fremanzumab, Eptinezumab, Rimegepant, Atogepant destined for the centers of the field of Valencian public health.local title:: Suministro d e medicamentos antimigrañosos con los siguientes principios activos, erenumab, galcanezumab, fremanezumab, eptinezumab, rimegepant, atogepant con destino a los centros del ámbito de la sanidad pública valenciana.Contract Type: : Supplylocal description: : Suministro de medicamentos antimigrañosos con los siguientes principios activos, erenumab, galcanezumab, fremanezumab, eptinezumab, rimegepant, atogepant con destino a los centros del ámbit

Gt Ref Id - 114145853

Deadline - Nov 30, -0001